

VAXXON[®] Aviflu

Protection right from the start

- Effective protection against Avian Influenza A
- Safe and easy to use from 1 day old onwards



va:inova[®]

Avian Influenza

H9N2 subtype avian influenza viruses (AIVs) have been isolated from various species of wild birds and domestic poultry in the world, and occasionally transmitted to humans. ⁽¹⁾ In outbreaks of H9N2 AI reported in Iran, the isolate was characterized in the laboratory as of low pathogenicity (LP). However, mortality in the field approached 65% on some broiler farms. Lesions were identified only in the respiratory system, particularly the trachea and the bronchi. ⁽²⁾

H9N2 remains endemic across Asia, mainly limited to outbreaks in domestic land-based poultry, but overshadowed as a pandemic threat by H5N1 bird flu, which has spread from Asia into Africa and Europe. However, there is evidence of interspecies transmission of H9N2 from land-based poultry to mammals, such as pigs and swine. Further evidence of an expanded mammalian host range includes efficient replication of H9N2 in mice without adaptation. H9N2 has already caused mild respiratory disease in humans in Hong Kong and mainland China in 1999 and 2003. ⁽³⁾

Among low pathogenicity AIV (LPAIV), Eurasian H9N2 have been endemic in the domestic poultry population across North Africa, the Middle East and Asia since its emergence in China during 1994. These viruses are responsible for severe economic losses due to declined egg production and moderate to high mortality in broiler-type chickens. ⁽⁴⁾ In various outbreaks, inactivated influenza virus vaccines have been used successfully. ⁽⁵⁾

Sources:

- 1 - Dongdong Wang, Jingjing Wang, et All - Characterization of avian influenza H9N2 viruses isolated from ostriches (*Struthio camelus*) - Scientific Reports volume 8, Article number: 2273 (2018)
- 2 - H. Nili and K. Asasi - Avian Influenza (H9N2) Outbreak in Iran - Avian Diseases, 47(s3):828-831. 2003
- 3- Paul E Alexander, et all - Is H9N2 avian influenza virus a pandemic potential? - Can J Infect Dis Med Microbiol. 2009 Summer; 20(2): e35-e36.
- 4- Klaudia Chrzastek, et all - Characterization of H9N2 avian influenza viruses from the Middle East demonstrates heterogeneity at amino acid position 226 in the hemagglutinin and potential for transmission to mammals - Virology. 2018 May;518:195-201
- 5- Bahl, A. K., and B. S. Pomeroy. Efficacy of avian influenza oil-emulsion vaccine in breeder turkeys. J. Am. Vet. Med. Assoc. 171:1105. 1977



VAXXON® Aviflu - Protection right from the start



Indications

Active immunization against Avian Influenza A.



Active Substance

Inactivated Avian Influenza virus A, subtype H9N2



Administration Route

Broiler: 0.2 ml per chick at day old subcutaneously.

Layers & Breeders: 0.2 ml per bird from day old up to 3 weeks. Revaccinations at 8 weeks and between 12-16 weeks are recommended with a dose of 0.5 ml intramuscular.



Poultry Category

Chickens (broilers, layers and breeders).



Age of Vaccination

Broilers: day old chicks.

Layers: from day old up to 3 weeks. Revaccination recommended at 8 weeks and between 12-16 weeks.



Presentation

500 ml bottles – equal to 1000 doses.



Shelf life

Packaged product for sale: 24 months.

After opening: 10 hours.



Storage conditions

Store and transport at a temperature between + 2 ° C and + 8 ° C.

Do not freeze.

Keep in the original package in order to protect from light.

DISCLAIMER

This brochure may contain information or may show or refer to products and/or services which are only available in certain countries. A reference to any product/service in this brochure does not imply that such product or such product with the same specifications et cetera, is or will be available at your location. Any product shown or referred to in this brochure may be subject to different regulatory requirements depending on the country of use. Please contact your local Vaxxinova representative for more information.

Vaxxinova International BV does not give any warranty or other assurance as to the content of this brochure, its accuracy, completeness, timelessness or fitness for any particular purpose. To the full extent permissible by law, Vaxxinova International BV disclaims all responsibility for any damages or losses (including without limitation, financial loss, damages for loss in business projects,

loss of profits or other consequential losses) arising in contract, tort or otherwise from the use of inability to use any material of Vaxxinova, or from any action or decision taken as a result of using Vaxxinova's materials. Vaxxinova disclaims all responsibility and liability (including for negligence) in relation to information mentioned in Vaxxinova's materials. This document or its content is not to be copied or further distributed without the consent of Vaxxinova International BV.

VAXXINOVA, VAXXON and GOVAXX are registered trademarks of Vaxxinova International B.V. (the Netherlands).

Version 4
2024.12
120979



Scan for more
Vaxxinova vaccine solutions



Vaxxinova International BV

Transistorweg 5
6534 AT Nijmegen
The Netherlands
+31 24 20 48 600
www.vaxxinova.com

va  **inova**®